ONC: רווח נקי למניה (EPS TTM) BeiGene Ltd

Geopolitical pressure and testing costs create risks for BeiGene Ltd (ONC), as confirmed by the fundamental EPS TTM metric, where the value remains at 7.86. BeiGene Ltd (ONC) is implementing targeted therapy to reduce treatment toxicity. Meanwhile, high margins in the West are offset by strict government price regulations in China, which limit business profitability.

This metric determines the portion of the final financial result attributable to a single common share by dividing the total annual profit by the total number of securities. By analyzing the net income per share over a rolling 12-month period, an investor can see how the expansion of Brukinsa and the launch of new therapies translate into actual return on capital against the backdrop of massive R&D expenditures for BeiGene Ltd (ONC).